Full Text View
Tabular View
Study Results
Related Studies
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults
This study has been completed.
Study NCT00560313   Information provided by Novartis

First Received on November 16, 2007.   Last Updated on December 8, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Meningococcal Disease
Additional conditions recognized in this trial
Meningococcal Infections
More general conditions related to this trial
Bacterial Infections
Gram-Negative Bacterial Infections
Neisseriaceae Infections
Interventions listed in this trial
Men ACWY CRM
4CMenB
Sponsors listed in this trial
Novartis Vaccines


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services